A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

NCT04657224 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Non-Hodgkin
Chronic Lymphocytic Leukemia

Interventions

DRUG: JNJ-64264681
DRUG: JNJ-67856633

Sponsor

Janssen Research & Development, LLC